NCT06645236not applicablerecruiting

DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit

QIAGEN Gaithersburg, Inc

ClinicalTrials.gov

600

Enrollment · estimated

Countries · 1 sites

2030-10

Primary completion

1 yr ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
46/100
Opportunity
New not applicable trial NCT06645236 posted by QIAGEN Gaithersburg, Inc: "DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit".
ClinicalTrials.gov record updated 389 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* Subjects who consent to participate in the eligibility screen for Protocol 20210081 will have their tumor tissue tested for the presence of KRAS G12C mutation under the proposed performance study.

Exclusion Criteria:

* There is no separate inclusion and exclusion criteria for the performance study.